The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Potassium Phosphates
Potassium Phosphate, Monobasic Potassium Phosphate, Dibasic · MONOBASIC POTASSIUM PHOSPHATE 224 mg/mL; DIBASIC POTASSIUM PHOSPHATE 236 mg/mL · Injection, Solution, Concentrate · Intravenous · Fresenius Kabi USA, LLC
NDC 65219-0056-29 · 25 VIAL in 1 TRAY / 50 mL in 1 VIAL · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$2,967.75
Reported to Texas DSHS · 2026 annual filing · Fresenius Kabi USA
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicaid spend (2025)
$4.3M
6,929 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Fresenius Kabi USA, LLCUnited Statesanalysis · manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program · Xywav and Xyrem
Regulatory
- Application
- NDA212832
- TE code
- AP
- Approval date
- Nov 26, 2019
- Patents / exclusivity
- 4 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 11925661 | Oct 12, 2041 |
| patent | 11925661 | Oct 12, 2041 |
| patent | 11813291 | Oct 12, 2041 |
| patent | 11813291 | Oct 12, 2041 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Potassium Phosphate, Monobasic Potassium Phosphate, Dibasic (Injection, Solution, Concentrate)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Fresenius Kabi USA, LLC | MONOBASIC POTASSIUM PHOSPHATE 224 mg/mL; DIBASIC POTASSIUM PHOSPHATE 236 mg/mL | Aug 26, 2026 | Sep 3, 2026 |
| Civica, Inc. | MONOBASIC POTASSIUM PHOSPHATE 224 mg/mL; DIBASIC POTASSIUM PHOSPHATE 236 mg/mL | Aug 26, 2026 | Sep 2, 2026 |
| Fresenius Kabi USA, LLC | MONOBASIC POTASSIUM PHOSPHATE 236 mg/mL; DIBASIC POTASSIUM PHOSPHATE 224 mg/mL | Jul 22, 2026 | Aug 22, 2026 |
| Civica, Inc. | MONOBASIC POTASSIUM PHOSPHATE 236 mg/mL; DIBASIC POTASSIUM PHOSPHATE 224 mg/mL | Jul 22, 2026 | Aug 19, 2026 |
| Civica, Inc. | DIBASIC POTASSIUM PHOSPHATE 236 mg/mL; MONOBASIC POTASSIUM PHOSPHATE 224 mg/mL | Jul 15, 2026 | Jul 15, 2026 |
| Fresenius Kabi USA, LLC | DIBASIC POTASSIUM PHOSPHATE 236 mg/mL; MONOBASIC POTASSIUM PHOSPHATE 224 mg/mL | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Potassium Phosphates — NDC 65219-0056-29," retrieved September 3, 2026, https://drugdashboards.com/drug/65219005629.
Free to cite with attribution — see how the data is put together.